A Clinical Trial of Infliximab for Childhood Uveitis

Xiaomin Zhang (Other)
Overall Status
Active, not recruiting
CT.gov ID

Study Details

Study Description

Brief Summary

This project is designed to test the hypothesis that infliximab is clinically useful for patients with refractory childhood uveitis.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, and the off-label use of infliximab, its potential risks and benefits. This is a prospective non-comparative interventional study.

Participants will receive intravitreal injections of suggested dose of infliximab (5 mg/kg/dose) and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 10 months to determine efficacy and side effects, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period.

Study Design

Study Type:
Anticipated Enrollment :
10 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
A Clinical Trial of Infliximab for Injection in Refractory Childhood Uveitis
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Jan 1, 2020
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with Childhood Uveitis

5mg/kg/dose of infliximab IV initially two weeks, then 4 weeks and then every 6-8 weeks

Drug: infliximab
Other Names:
  • Remicade
  • Outcome Measures

    Primary Outcome Measures

    1. Change In LogMAR Best Corrected Visual Acuity (BCVA) From Baseline to Each Visit. [24 weeks]

      Participant's best corrected visual acuity was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart. On the logMAR scale, 0 is equivalent to 20/20 visual acuity, the range of normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.

    Secondary Outcome Measures

    1. Change in Anterior Chamber (AC) Cell Grade From Baseline to Each Visit. [24 weeks]

      Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = < 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = > 50 cells.

    2. Change in Vitreous Haze (VH) Grade From Baseline to Each Visit. [24 weeks]

      Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.

    Eligibility Criteria


    Ages Eligible for Study:
    4 Years to 18 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Ages 4 to 18 years old,

    • Non-infectious uveitis

    • Persistent uveitis uncontrolled by topical medications, or unacceptable side effects of topical medications.

    • Failure of at least six weeks of treatment with a non-biological disease modifying agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.

    • Ability to provide informed consent (subject or parent/guardian)

    • Onset of uveitis < 16 years of age.

    • Topical ophthalmologic treatments allowed.

    • Systemic corticosteroid use at entry may be allowed.

    • Participant must be able to cooperate for a non-sedated slit lamp exam and visual acuity examination.

    • Negative Purified Protein Derivative (PPD) placed and read within 1 month of initiation of infliximab

    • The screening laboratory test results must meet the following criteria:

    WBC (white blood cell count): within normal range for institution ANC (absolute neutrophil count): within normal range for institution Hemoglobin: greater than 10 grams/deciliter Platelets: within normal range for institution Serum Creatinine: within normal range for age AST - aspartate aminotransferase - within normal range for institution ALT - alanine aminotransferase- within normal range for institution

    Exclusion Criteria:
    • Previous use of biologic medications for uveitis.

    • Intraocular steroid injection or ophthalmologic surgery within the preceding 3 months.

    • Uveitis due to trauma or intraocular surgery

    • A history of a known allergy to murine products.

    • Documentation of seropositivity for human immunodeficiency virus (HIV).

    • Documentation of a positive test for hepatitis B surface antigen or hepatitis C

    • A known history of a serious infection (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.

    • An opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.

    • A concomitant diagnosis or history of congestive heart failure.

    • A history of lymphoproliferative disease.

    • Any known malignancy or a history of malignancy.

    • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

    • Use of any investigational drug within 30 days prior to screening or within five half-lives of the first dose of the investigational agent, whichever is longer.

    • Presence of a transplanted solid organ.

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • Xiaomin Zhang


    • Study Director: Xiaomin Zhang, M.D., Tianjin Medical University Eye Hospital

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Xiaomin Zhang, Principal Investigator, MD, PhD, Tianjin Medical University
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • 2017KY-05
    First Posted:
    Nov 5, 2019
    Last Update Posted:
    Nov 2, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Product Manufactured in and Exported from the U.S.:
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 2, 2021